Platform for enhanced targeted delivery
AssigneeBaylor College of Medicine
InventorsNabil M. Ahmed, Hebatalla S. Samaha, Antonella Pignata, Kristen Fousek
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.
Claims27
A therapeutic composition comprising
- a) at least one therapeutic moiety;
- said moiety operably linked to one or more of
- b) adhesion molecule binding moiety, wherein the adhesion molecule is ALCAM and the binding moiety is part or all of cluster of differentiation 6 (CD6).
A therapeutic composition comprising:
- a) at least one therapeutic moiety;
- said moiety operably linked to one or more of
- b) adhesion molecule binding moiety, wherein the adhesion molecule is ICAM-1 and the binding moiety for ICAM-1 comprises part or all of MAC-1 and/or part or all of LFA-1.
A therapeutic composition comprising:
- a) at least one therapeutic moiety;
- said moiety operably linked to one or more of
- b) adhesion molecule binding moiety, wherein the adhesion molecule is JAM-1 and the binding moiety for JAM-1 comprises part or all of MAC-1 and/or part or all of LFA-1.
A therapeutic composition comprising:
- a) at least one therapeutic moiety;
- said moiety operably linked to one or more of
- b) adhesion molecule binding moiety, wherein the adhesion molecule is GLYCAM-1 and the binding moiety for GLYCAM-1 comprises part or all of LPAM-1.
A therapeutic composition comprising:
- a) at least one therapeutic moiety;
- said moiety operably linked to one or more of
- b) adhesion molecule binding moiety, wherein the adhesion molecule is Addressin and the binding moiety for Addressin comprises part or all of LPAM-1.
Dependencies are inferred from the claim text.